Related Experiment Video
Updated: May 10, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
[Drug treatments, from chlorpromazine to new molecules]
Adeline Gaillard1, Marie-France Poirier
1Service hospitalo-universitaire de santé mentale et thérapeutique du Pr Marie-Odile Krebs, Centre Hospitalier Sainte-Anne, Paris Cedex, France. a.gaillard@ch-sainte-anne.fr
Abstract:
The history of drug treatments, and particularly the discovery of certain molecules, led toan evolution in psychiatric practices. The discovery of the therapeutic properties of chlorpromazine in 1952 by Jean Delay and Pierre Deniker revolutionised the relational process between patients and caregivers.The perspectives are encouraging, notably in the areas of schizophrenia and mood disorders.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Antipsychotic Drugs: Typical and Atypical Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

